SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs (India) informs about transcript of conference call

14 Jun 2024 Evaluate

Kilitch Drugs (India) has informed that it enclosed a copy of the transcript of the Company's Q4 FY24 earnings conference call dated 10th June, 2024.

The above information is a part of company’s filings submitted to BSE.

Kilitch Drugs(India) Share Price

182.90 0.55 (0.30%)
19-Jun-2026 11:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1827.30
Dr. Reddys Lab 1263.00
Cipla 1353.70
Zydus Lifesciences 1074.15
Lupin 2329.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: